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Abstract
Well validated antibodies are crucial to progress in a wide range of life science
disciplines, but validating an antibody is a complex and ongoing process.
Antibody validation is often carried out as preliminary work to a larger study so
the validation data may go unpublished and needless duplication of efforts can
occur. This collection of articles in  provides a home for papersF1000Research
describing antibody validation studies. Our goal is to encourage publishing of
all studies, both positive and negative, which increase understanding of how
antibodies perform. These could range from large studies with thousands of
antibodies to small single figure studies which validate an individual antibody
for a specific purpose. Opinion or Correspondence articles considering any
aspect of antibody validation are also welcome. Here, we provide an
introduction to the collection which we hope will grow and become a valuable
resource for the many thousands of researchers who use antibodies.
 This article is included in the Antibody validations
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Editorial
Well validated antibodies are crucial to enable scientists to make 
progress in a wide range of life science disciplines ranging from 
Neuroscience to Tissue Engineering to Plant Science. Evidence of 
validation is important as it allows scientists to choose antibodies 
that are fit for their experiments and avoid wasting time optimis-
ing antibodies that are unsuitable. Validation data also provides 
reviewers a guide as to whether the antibodies used in a manuscript 
are likely to give reliable results, something which helps to ensure 
experimental reproducibility, a topical issue in today’s life sciences.
Validating an antibody is a complicated process that can involve many 
different approaches (Bordeaux et al., 2010; Howat et al., 2014). 
Historically antibody validation commonly involved the now con-
troversial antigen pre-adsorption test (Holmseth et al., 2012), while 
current studies may make use of knockout or knockdown tissue 
to demonstrate specificity. There are also large scale approaches, 
capable of validating many antibodies simultaneously (Holm et al., 
2012). However, there is no simple experiment that can validate 
an antibody for all possible applications and samples. For exam-
ple, validating an antibody for western blotting using a human cell 
line, does not guarantee the antibody will be suitable in immuno-
histochemistry using tissue from a rat. Instead antibody validation 
is a gradual process which involves testing the antibody for specific 
applications and species/tissues of interest, ideally using a number 
of approaches.
This collection provides a home for papers describing antibody 
validation studies. Our aim is to encourage publishing of all stud-
ies, both positive and negative, which increase understanding of 
how antibodies perform. These can range from large studies involv-
ing hundreds of antibodies, or the use of many tissues or cell lines, 
to small single figure studies focusing on an individual antibody 
in a specific setting. The studies should have been sufficiently 
repeated and the results accurately and fully reported. It is also 
crucial that the Materials and methods provide enough detail to 
allow the experiments to be reproduced, something which is often 
not the case with studies using antibodies (Helsby et al., 2013). 
A key part of ensuring reproducibility is to make sure the antibodies 
can be identified by including their supplying company name and 
code and a resource identifier issued by the Research Identification 
Initiative (http://scicrunch.com/resources).
The instructions to authors (Box 1) and guidelines for reviewers 
have been tailored to facilitate the aim of encouraging a broad range 
of papers, with a focus on reproducibility and accurate reporting, 
rather than perceived impact. Correspondence and Opinion articles 
on any aspect of antibody validation are also welcomed.
Box 1. Extract from the Instructions to Authors
The Antibody validation article collection aims to provide a 
platform for antibody validation studies and enhance the reliability 
and reproducibility of antibodies in scientific research. Referees 
reviewing validation studies will not focus on novelty and impact, 
but rather on whether the study is scientifically sound and 
provides all relevant information. 
F1000Research accepts a variety of validation studies, which will 
be published as Research Notes:
• New antibodies; either against a new target or a new 
antibody raised against an existing target.
• New applications for existing antibodies; either in a new 
biological system or a new application tested within an 
existing/previously tested biological system.
• Existing antibody applied to a new biological system; new 
organism/tissue/cell type.
• Validations of previously tested antibodies that are carried 
out in more depth than before, in one or more applications.
• Validations of groups of antibodies raised against the same 
target.
• Antibodies that failed to meet the validation criteria.
• Replication studies that confirm or disagree with previously 
published validations.
This broad approach should encourage a wide range of studies, 
many of which may never be published without this initiative and 
we hope that as the collection grows it will become a valuable 
resource for the thousands of researchers who use antibodies.
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      Amendments from Version 1
After recent discussions we have decided to also include Antibody 
Validation studies performed by companies in this collection. 
Therefore, we have removed mentions of the requirement that 
studies be “independent”. 
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